The short version of half-life fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-13. Anything still debated is marked as such rather than presented as settled.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
Stability studies focus on deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation into higher-order species. The fatty acid side chain adds susceptibility to oxidative change and can promote self-association at high concentration. Lyophilised material is comparatively robust when kept cold and dry, while aqueous solutions require refrigeration and protection from light. Forced degradation experiments under heat, acid, base, and peroxide conditions establish the specificity of each analytical method. Which degradation route dominates under real storage conditions depends on the formulation and stays formulation-specific.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Cromoglicic acid (INN)—also referred to as cromolyn (USAN), cromoglycate (former BAN), or cromoglicate—is traditionally described as a mast cell stabilizer, and is commonly marketed as the sodium salt sodium cromoglicate or cromolyn sodium. This drug prevents the release of inflammatory chemicals such as histamine from mast cells. It is considered a breakthrough drug in management of asthma, as the patients can be freed from steroids in many cases; however, it is mainly effective as a prophylaxis for allergic and exercise-induced asthma, not as a treatment for acute asthma attacks. Cromoglicic acid has been the non-corticosteroid treatment of choice in the treatment of asthma, for which it has largely been replaced by leukotriene receptor antagonists because of their safety and convenience. Cromoglicic acid requires administration four times daily, and does not provide additive benefit in combination with inhaled corticosteroids.
The target material is exposed an external source of radiation. The radiation source supplies energetic particles or electromagnetic waves. These particles or waves collide with material in the target. The higher the likelihood of these collisions over a distance are, the lower the penetration depth of the irradiation process is as the energy is more quickly depleted. These collisions break chemical bonds, creating short lived radicals (e.g. the hydroxyl radical, the hydrogen atom and solvated electrons). These radicals cause further chemical changes by bonding with and or stripping particles from nearby molecules. When collisions occur in cells, cell division is often suppressed, halting or slowing the processes that cause the food to mature. When the process damages DNA or RNA, effective reproduction becomes unlikely halting the population growth of viruses and organisms. The distribution of the dose of radiation varies from the food surface and the interior as it is absorbed as it moves through food and depends on the energy and density of the food and the type of radiation used.
Weinberg's statement is true as far as it goes, but it is not the whole truth. To make it the whole truth, we must add an additional clause: "And for bad people to do good things – that [also] takes religion." The main point of Christianity is that it is a religion for sinners. Jesus made that very clear. When the Pharisees asked his disciples, "Why eateth your Master with publicans and sinners?" he said, "I come to call not the righteous but sinners to repentance." Only a small fraction of sinners repent and do good things but only a small fraction of good people are led by their religion to do bad things. Dyson identified himself as agnostic about some of the specifics of his faith. For example, in reviewing The God of Hope and the End of the World by John Polkinghorne, Dyson wrote:
Sources: en.wikipedia.org
=== 118th Congress (2023–2025) === By late 2022, there was again speculation that Kennedy might run for governor in the 2023 election, when Edwards would be term limited, but he ended the rumors on the second day of the 118th Congress by announcing he again would prefer to stay in the Senate. On January 25, 2023, Kennedy quizzed Biden's judicial nominee Charnelle Bjelkengren on basic questions about the Constitution of the United States, whether she could state the functions of Articles V and II, and whether she could define purposivism and the independent state legislature theory. Bjelkengren failed to answer all four questions. After the hearing, Kennedy told a local reporter at NBC News, "Some of these nominees that have been forced in the last two years have no business being anywhere near a federal bench—they don't have any business being anywhere near a park bench." Bjelkengren later withdrew her nomination. In May 2023, Kennedy sparked a diplomatic row with Mexico after he said, "Without the people of America, Mexico, figuratively speaking, would be eating cat food out of a can and living in a tent", while asking DEA Administrator Anne Milgram why the U.S. was not asking Mexico to partner more effectively with the U.S. to stop the flow of fentanyl over the border. Kennedy introduced a bill to classify drug cartels as terrorist organizations because they traffic fentanyl, a drug that killed more than 70,000 Americans in 2022. He also introduced a bill in 2023 to increase the prison sentences for fentanyl dealers, saying, "You have to have 400 grams. . .
These initially involved groups of soldiers that were inserted by helicopter, and were later expanded with paratroopers. The Rhodesian Light Infantry often provided the soldiers for fireforce teams. A key element of the Selous Scouts' methods was 'turning' captured insurgents to join the Rhodesian security forces. This was normally attempted shortly after insurgents were captured, with them being both threatened and offered incentives. The captured insurgent was usually approached by a former insurgent. In the resulting conversation, the former insurgent emphasised the hardships insurgents were experiencing and that those who were captured faced the death penalty under the Law and Order (Maintenance) Act. This legislation imposed severe penalties for people found to be members of subversive organisations, including the death penalty or long prison terms. The captured insurgent was also offered a lump sum payment as well as a soldier's salary if they agreed to fight for the Rhodesian government. If an insurgent agreed to be 'turned' and passed further vetting, they were assigned to a Selous Scout team and operated in regions in which they would not be recognised. Where possible, their family was housed on a Selous Scouts base. Only a small number of 'turned' insurgents ever deserted or betrayed the unit. Some of the prisoners captured by the Selous Scouts who refused to be 'turned' were killed. One of the tactics used by the Selous Scouts was to violate local customs while posing as insurgents with the goal of reducing support for the actual insurgents.
=== People's Republic === In 1950, CCP chairman Mao Zedong announced support of traditional Chinese medicine; this was despite the fact that Mao did not personally believe in and did not use TCM, according to his personal physician Li Zhisui. In 1952, the president of the Chinese Medical Association said that, "This One Medicine, will possess a basis in modern natural sciences, will have absorbed the ancient and the new, the Chinese and the foreign, all medical achievements – and will be China's New Medicine!" During the Cultural Revolution (1966–1976), the CCP and the government emphasized modernity, cultural identity, and China's social and economic reconstruction and contrasted them to the colonial and feudal past. The government established a grassroots health care system as a step in the search for a new national identity, tried to revitalize traditional medicine, and made large investments in traditional medicine to try to develop affordable medical care and public health facilities. The Ministry of Health directed health care throughout China and established primary care units. Chinese physicians trained in Western medicine were required to learn traditional medicine, while traditional healers received training in modern methods. This strategy aimed to integrate modern medical concepts and methods and revitalize appropriate aspects of traditional medicine. Therefore, traditional Chinese medicine was re-created in response to Western medicine.
One prominent general, Alexios I, usurped the throne in 1081. In contrast to the prior turmoil, the three reigns of Alexios (r. 1081–1118), his son John II (r. 1118–1143), and his grandson Manuel I (r. 1143–1180) lasted almost a century and restored the empire's regional authority for the final time. Alexios immediately faced the Normans under Robert Guiscard and repelled them through warfare and diplomacy. He then targeted the Pechenegs and decisively defeated them in 1091 with help from the Cumans; a separate Cuman incursion followed in 1094. Finally, looking to recover Asia Minor from the Seljuks, he approached Pope Urban II for help c. 1095. The scale and aims of western Christendom's response exceeded Byzantine expectations: the First Crusade helped restore parts of western Anatolia to Byzantine control, although Alexios and its leaders soon fell out. The rest of his reign was spent dealing with the Normans and Seljuks, establishing a new, loyal aristocracy to ensure stability, and carrying out fiscal and ecclesiastical reforms.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
Purity is commonly expressed as the percentage of the main peak relative to all integrated peaks in a reversed-phase chromatogram. Related substances and counter-ions are reported separately. Values obtained with different detectors are not always directly comparable.